4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 性质
熔点 | 87 - 89°C |
---|---|
储存条件 | 2-8°C |
溶解度 | 溶于DMSO(>25mg/ml) |
形态 | 粉末 |
颜色 | 白色至米色 |
稳定性 | 供货时可稳定保存 1 年。 DMSO 溶液可在 -20°C 下保存长达 3 个月。 |
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 用途与合成方法
Target | Value |
SERCA
() |
CDN1163 (5.5-25 mM; 0-8 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.
Western Blot Analysis
Cell Line: | Rat cardiac myocyte cells (H9c2) |
Concentration: | 5.5 mM, 25 mM |
Incubation Time: | 0 hour, 4 hours, 8 hours |
Result: | High glucose-induced resistin and nuclear NFATc expression were significantly reduced. The phosphorylation of AMPKα is increased in a time-dependent manner. |
CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca 2+ -ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca 2+ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo.
Animal Model: | Male 8-10-week old ob/ob mice and lean ob/+ mice |
Dosage: | 50 mg/kg |
Administration: | Intraperitoneal injection; for 5 days |
Result: | Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway. |
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-101455 | 1 mg | 350 | ||
2024-11-08 | HY-101455 | 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 | 892711-75-0 | 5mg | 770 |